ArticleBMC pediatrics2025
The therapeutic effects of ketogenic diet, lacosamide, and combination therapy in children with refractory epilepsy.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quality of Life and Associated Factors in Primary Caregivers of Children with Refractory Epilepsy on Long-Term Ketogenic Diet: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIntractable epilepsy in children poses significant clinical challenges due to limited efficacy of conventional anti-epileptic drugs (AEDs), leading to persistent neurodevelopmental impairments. This study investigated the therapeutic effects of ketogenic diet (KD), lacosamide (LCM), and their combination on refractory epilepsy, with comprehensive assessment of seizure control, EEG dynamics (including epileptiform patterns and spectral characteristics), cognitive function, lipid metabolism, and endothelial health.
methodsNinety children with refractory epilepsy were divided into three treatment groups: KD (n = 30), LCM (n = 30), and KD + LCM (n = 30). Assessments included detailed EEG characterization (seizure types, interictal discharges, spectral bands), cognitive testing (attention/memory), lipid profiles, and endothelial markers at baseline, 3-, and 6-months post-treatment.
resultsThe KD + LCM group showed superior seizure reduction at 3/6 months (t = 2.171, P = 0.035; t = 3.177, P = 0.003), with 76.7% achieving ≥ 50% interictal discharge reduction (P = 0.008) and 63.3% seizure type simplification (P = 0.003) at 6 months. Cognitive performance significantly improved (attention: Δ=-10.8 ± 2.0; memory: Δ=-9.4 ± 1.8; both P < 0.001), strongly correlating with frontal θ-band modulation (|r|>0.68). Combination therapy also enhanced α/β/δ/θ spectral power (P ≤ 0.019), improved lipid profiles, and restored endothelial function versus monotherapies (all P < 0.05).
conclusionsKD and LCM combination therapy provides comprehensive benefits-superior seizure control, EEG normalization, cognitive enhancement, metabolic optimization, and vascular protection-making it a promising multimodal approach for refractory epilepsy management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.